Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis
Số trang: 11
Loại file: pdf
Dung lượng: 912.93 KB
Lượt xem: 6
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice.
Nội dung trích xuất từ tài liệu:
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis
Nội dung trích xuất từ tài liệu:
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Neuroendocrine tumours Somatostatin analogues Clinical practice Cross-sectional analysis Combination treatmentGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 92 0 0
-
19 trang 74 0 0
-
17 trang 63 0 0
-
9 trang 42 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0